To Get Help Now
Click Here
 
Today's Date:

Fosamsax, Boniva, Reclast Femur Fracture Lawsuits Consolidated

AddThis Social Bookmark Button

Fosamax, Reclast, and Boniva all belong in class of drugs known as bisphosphonates, and are designed to prevent bone loss that can occur during menopause as osteoporosis. However, the FDA imposed new warnings regarding bisphosphonates  and the link between long-term use and an increased risk of atypical femur fractures. The warning says that consumers should seek medical attention as soon as they experience groin or thigh pain while taking the drugs, which can sometimes signal a forthcoming thigh bone fracture, which often occurs with little to no trauma.

The U.S. Judicial Panel on Multidistrict Litigation issued on order on February 3, that all federally filed lawsuits which claim femur fractures by individuals taking both Reclast and Fosamax, or Boniva and Fosamax, or all three drugs, will be consolidated with Fosamax only lawsuits, which were consolidated under Judge Garrett E. Brown in the U.S. District Court for the District of New Jersey as part of multidistrict litigation. The Judicial Panel decided that even though they are three separate medications manufactured by three separate entities, there are common questions of fact that justify case consolidation.

Reclast is manufactured by Novartis as a once-a-year injectable medication. Boniva is manufactured by Roche as a once-a-month oral medication, and Fosamax is a weekly, daily, or monthly oral tablet or solution manufactured by Merck.

 

breakinglawsuitnews.com disclaimer: This article: Fosamsax, Boniva, Reclast Femur Fracture Lawsuits Consolidated was posted on Wednesday, February 8th, 2012 at 9:25 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Comments are closed.